Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Selective COX‐2 inhibitors vs NSAIDs

Return to work · Patients with acute low‐back pain

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute low back pain 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective COX‐2 inhibitors vs NSAIDs

Change in pain intensity from baseline on VAS (0 to 100) short‐term · Patients with acute low‐back pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute low back pain 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 437 participants
Low

Selective COX‐2 inhibitors vs NSAIDs

Disability ODI (0 to 50; lower = better) · Patients with acute low‐back pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute low back pain 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 437 participants
Moderate

Selective COX‐2 inhibitors vs NSAIDs

Proportion of participants experiencing global improvement % of dichotomized Likert scale · Patients with acute low‐back pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute low back pain 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 333 participants
Low

Selective COX‐2 inhibitors vs NSAIDs

Proportion of participants experiencing adverse events · Patients with acute low‐back pain

It is very uncertain whether selective COX‐2 inhibitors changes proportion of participants experiencing adverse events compared with non‐selective NSAIDs (very low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute low back pain 2020 · Cochrane Headline outcomes only
RR 0.97 [0.63, 1.5]
2 studies · 444 participants
Very low